| Tumor-associated macrophages in breast cancer: Innocent bystander or important player? SQ Qiu, SJH Waaijer, MC Zwager, EGE de Vries, B van der Vegt, ... Cancer treatment reviews 70, 178-189, 2018 | 448 | 2018 |
| Heart failure stimulates tumor growth by circulating factors WC Meijers, M Maglione, SJL Bakker, R Oberhuber, LM Kieneker, ... Circulation 138 (7), 678-691, 2018 | 327 | 2018 |
| Tumor-specific uptake of fluorescent bevacizumab–IRDye800CW microdosing in patients with primary breast cancer: a phase I feasibility study LE Lamberts, M Koch, JS de Jong, ALL Adams, J Glatz, MEG Kranendonk, ... Clinical Cancer Research 23 (11), 2730-2741, 2017 | 294 | 2017 |
| cGAS–STING drives the IL-6-dependent survival of chromosomally instable cancers C Hong, M Schubert, AE Tijhuis, M Requesens, M Roorda, ... Nature 607 (7918), 366-373, 2022 | 226 | 2022 |
| Exploiting metabolic acidosis in solid cancers using a tumor-agnostic pH-activatable nanoprobe for fluorescence-guided surgery FJ Voskuil, PJ Steinkamp, T Zhao, B van der Vegt, M Koller, JJ Doff, ... Nature communications 11 (1), 3257, 2020 | 157 | 2020 |
| Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers M Koller, SQ Qiu, MD Linssen, L Jansen, W Kelder, J de Vries, I Kruithof, ... Nature communications 9 (1), 3739, 2018 | 146 | 2018 |
| 89Zr-trastuzumab PET supports clinical decision making in breast cancer patients, when HER2 status cannot be determined by standard work up F Bensch, AH Brouwers, MN Lub-de Hooge, JR de Jong, B van der Vegt, ... European journal of nuclear medicine and molecular imaging 45, 2300-2306, 2018 | 140 | 2018 |
| Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment K Delli, EA Haacke, FGM Kroese, RP Pollard, S Ihrler, B van der Vegt, ... Annals of the Rheumatic Diseases 75 (11), 1933-1938, 2016 | 115 | 2016 |
| Fluorescence-guided imaging for resection margin evaluation in head and neck cancer patients using cetuximab-800CW: a quantitative dose-escalation study FJ Voskuil, SJ de Jongh, WTR Hooghiemstra, MD Linssen, PJ Steinkamp, ... Theranostics 10 (9), 3994, 2020 | 108 | 2020 |
| Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement T Koopman, HJ Buikema, H Hollema, GH de Bock, B van der Vegt Breast cancer research and treatment 169, 33-42, 2018 | 102 | 2018 |
| Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration SCY Leung, TO Nielsen, LA Zabaglo, I Arun, SS Badve, AL Bane, ... Histopathology 75 (2), 225-235, 2019 | 99 | 2019 |
| Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study) JF van Nimwegen, E Mossel, GS van Zuiden, RF Wijnsma, K Delli, AJ Stel, ... The Lancet Rheumatology 2 (3), e153-e163, 2020 | 98 | 2020 |
| Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren’s syndrome are not predictive for parotid MALT lymphoma development EA Haacke, B van der Vegt, A Vissink, FKL Spijkervet, H Bootsma, ... Annals of the rheumatic diseases 76 (10), 1781-1784, 2017 | 96 | 2017 |
| B cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome GM Verstappen, FGM Kroese, PM Meiners, OB Corneth, MG Huitema, ... The Journal of rheumatology 44 (1), 49-58, 2017 | 83 | 2017 |
| Imaging in primary Sjögren’s syndrome MS van Ginkel, AWJM Glaudemans, B van der Vegt, E Mossel, ... Journal of clinical medicine 9 (8), 2492, 2020 | 81 | 2020 |
| Intraoperative imaging in pathology-assisted surgery FJ Voskuil, J Vonk, B van der Vegt, S Kruijff, V Ntziachristos, ... Nature biomedical engineering 6 (5), 503-514, 2022 | 78 | 2022 |
| The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma B Van Der Vegt, MAJ De Roos, JL Peterse, C Patriarca, J Hilkens, ... Histopathology 51 (3), 322-335, 2007 | 77 | 2007 |
| Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma H Hartog, HM Horlings, B van der Vegt, B Kreike, A Ajouaou, ... Breast cancer research and treatment 129, 725-736, 2011 | 76 | 2011 |
| Androgen and estrogen receptor imaging in metastatic breast cancer patients as a surrogate for tissue biopsies CM Venema, LH Mammatas, CP Schröder, M van Kruchten, G Apollonio, ... Journal of Nuclear Medicine 58 (12), 1906-1912, 2017 | 69 | 2017 |
| Pathological and biological differences between screen-detected and interval ductal carcinoma in situ of the breast MA de Roos, B van der Vegt, J de Vries, J Wesseling, GH de Bock Annals of surgical oncology 14, 2097-2104, 2007 | 63 | 2007 |
Truuske (G.H.) de BockHoogleraar Oncologische Epidemiologie UMCGEmail yang diverifikasi di umcg.nl
